Skip to main content

Advertisement

ADVERTISEMENT

Poster CS-101

Accelerated Closure of Recalcitrant Wounds with Novel Bio-film Disrupting Gel: a Case Series

Abstract Body: Background: In a busy suburban wound care center, we often see patients with multiple comorbidities presenting with chronic ulcerations. These patients are at high risk for amputation. Many of these wounds become recalcitrant to healing while using traditional wound care treatments.   Research supports that chronic wounds have biofilm and many stall in the late inflammatory phase of healing.  The use of a bio-film disrupting gel (BFDG) alone or with traditional and advanced wound treatment helps facilitate a return to the trajectory of healing and provides an environment conducive to wound closure. Methods: A bio-film disrupting gel was introduced into the wound care regimen as a single agent or in conjunction with advanced wound care dressing choices.  The dressings were changed according to individual patient and wound characteristic needs. Case series:  69 y.o. male; neuropathic lateral right foot ulcer with osteomyelitis, severe arterial disease, non-ambulatory x 6 months. Began BFDG 6/25/19. Complete closure and ambulating 9/30/19. a.  69 y.o. male; neuropathic lateral right foot ulcer with osteomyelitis, severe arterial disease, non-ambulatory x 6 months. Began BFDG 6/25/19. Complete closure and ambulating 9/30/19. b.  75 y.o. male; non-healing arterial leg ulcer x 4 weeks, PVD with claudication. Began BFDG 12/5/19. Complete closure 1/23/19. c.  84 y.o. male; Neuropathic, Stage IV Pressure Ulcer left plantar foot X 3 months.  Began BFDG 1/9/2019. Complete closure 3/25/2019. d.  72 y.o. male; uncontrolled DMII, Stage IV Pressure Ulcer Right heel with osteomyelitis x 8 months. Began BFDG on 5/22/19. Complete closure 9/12/19. Results: Immediate improvement in wound measurements, reduced drainage, complete closure and avoidance of amputation was seen in all patients. Analysis: Further investigation with this product is warranted, perhaps as a first line agent in chronic wounds since outcomes have been favorable in recalcitrant wounds.

Advertisement

Advertisement

Advertisement